Roche's TIG­IT fall­out caus­es GSK and iTeos to re-think their own I/O can­di­date

Both Glax­o­SmithK­line and iTeos Ther­a­peu­tics are go­ing to take a hard look at their ex­per­i­men­tal TIG­IT-tar­get­ing im­munother­a­py in the wake of Roche’s fail ear­li­er this …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER